GlassScriptPhysician profile
Kenneth C Onuoha
NPI 1902114424
$1,047.21
in general payments reported to CMS, 2019-2025
21 companies · $716 in 2025
The $716 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $116 · 2022: $84.92 · 2023: $94.13 · 2024: $35.49 · 2025: $716.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $846.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $845.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $95.59 | 2024-2025 | Verquvo |
| Novo Nordisk INC | $93.14 | 2022-2025 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $90.24 | 2019-2025 | Breztri, Airsupra |
| Alkermes, INC. | $84.10 | 2023-2025 | Aristada, Lybalvi, Vivitrol |
| Glaxosmithkline, LLC. | $80.87 | 2019-2025 | Trelegy Ellipta |
| Corcept Therapeutics | $74.79 | 2025 | Korlym |
| Lilly USA, LLC | $63.75 | 2025 | Jardiance, Mounjaro, Zepbound |
| Lundbeck LLC | $61.90 | 2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $52.80 | 2025 | Fanapt |
| Exact Sciences Corporation | $52.05 | 2025 | The Cologuard Plus Collection Kit |
| Mylan Specialty L.P. | $50.00 | 2022 | |
| Idorsia Pharmaceuticals US INC | $38.65 | 2023 | Quviviq |
| Abbvie INC. | $36.57 | 2019-2025 | |
| Pfizer INC. | $29.03 | 2019 | |
| Evoke Pharma, INC. | $27.72 | 2024-2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $24.97 | 2025 | |
| Abbott Laboratories | $23.69 | 2025 | Freestyle Libre 3 |
| Otsuka America Pharmaceutical, INC. | $20.23 | 2025 | Rexulti |
| Amgen INC. | $20.08 | 2025 | Otezla, Repatha |
| Phadia US INC. | $13.54 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Onuoha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.